What to Say When Requesting GLP-1 Options: The Exact Script That Gets You Past the Gatekeepers

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The most effective opening is "I'd like to discuss whether a GLP-1 medication is appropriate for my weight management" (not "I want Ozempic"), which frames the conversation as collaborative rather than demanding
• Bring documented BMI (current and 6-month history if available), prior weight-loss attempts with specific dates and methods, and any obesity-related comorbidities (prediabetes, hypertension, sleep apnea, NAFLD)
• If insurance denies coverage, the specific phrase "I'd like to explore compounded semaglutide or tirzepatide options" signals you've done research and opens the door to telehealth platforms
• Providers respond better to questions than demands: "What would you need to see to feel comfortable prescribing a GLP-1 medication?" is more effective than "I need a prescription today"

Direct answer (40-60 words)

Start with "I'd like to discuss whether a GLP-1 medication is appropriate for my weight management." Bring documented BMI, prior weight-loss attempts, and any obesity-related conditions. Ask what the provider needs to feel comfortable prescribing. If insurance coverage is denied, ask specifically about compounded semaglutide or tirzepatide options through telehealth platforms.

Table of contents

1. The opening line that works (and the one that backfires)
2. What most articles get wrong about this conversation
3. The documentation that moves the conversation forward
4. The insurance vs compounded decision tree
5. How to handle "let's try diet and exercise first"
6. The specific questions that signal you're an informed patient
7. When to mention brand names vs generic active ingredients
8. The FormBlends clinical pattern: what actually predicts prescription success
9. The script for different provider types (PCP vs endocrinologist vs telehealth)
10. What to do if your first request is denied
11. The contrary view: when providers are right to say no
12. FAQ
13. Sources

The opening line that works (and the one that backfires)

What works: "I'd like to discuss whether a GLP-1 medication is appropriate for my weight management. I've tried [specific methods] over the past [timeframe], and I'm looking for medical guidance on next steps."

This language does three things:

1. Frames the conversation as collaborative ("discuss whether") rather than transactional ("I want")
2. Uses the clinical term "GLP-1 medication" rather than brand names, which signals research without sounding like you're self-diagnosing from social media
3. Establishes that you've already attempted lifestyle modification, which is the clinical prerequisite for pharmacotherapy

What backfires: "I want Ozempic. I saw it on TikTok and everyone's losing weight."

This language signals:

1. You're requesting a specific brand based on social media, not medical indication
2. You may not understand the difference between diabetes and obesity indications
3. You haven't considered whether you meet clinical criteria

A 2024 survey of 340 primary care physicians published in Obesity (Chen et al.) found that 68% of providers reported patients requesting GLP-1 medications by brand name in the past year. Of those requests, providers prescribed the medication 41% of the time when the patient used collaborative language ("discuss whether appropriate") vs 18% when the patient demanded a specific brand.

The difference isn't about being polite. It's about signaling that you understand the provider needs to evaluate appropriateness, not just write what you ask for.

What most articles get wrong about this conversation

Most online guides treat the GLP-1 request conversation as a negotiation problem: how to convince a reluctant provider to prescribe. That framing is backwards.

The actual barrier isn't provider reluctance. It's information asymmetry. Providers need specific clinical data points to justify a prescription, both for medical appropriateness and for insurance authorization. Most patients don't know which data points matter.

The common advice is "be confident" or "advocate for yourself." That's not wrong, but it's not actionable. The actionable version is: bring the six data points that appear on every prior authorization form.

Those six points are:

1. Current BMI (calculated from measured height and weight, not self-reported)
2. BMI 6 months ago (if available)
3. Documented weight-loss attempts in the past 12 months (specific methods and durations)
4. Presence or absence of obesity-related comorbidities (type 2 diabetes, prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, NAFLD)
5. Current medications that might interact with GLP-1 agonists (insulin, sulfonylureas, warfarin)
6. History of pancreatitis, medullary thyroid cancer, or MEN2 syndrome (absolute contraindications)

If you walk in with those six points documented, the conversation shifts from "convince me" to "let's review the data." That shift is what most articles miss.

The documentation that moves the conversation forward

Bring printed or digital documentation of:

Your current BMI and weight history. Most insurance plans require BMI ≥30 kg/m² (or ≥27 kg/m² with at least one obesity-related comorbidity) for coverage. If you don't know your BMI, calculate it before the appointment. If you have weight measurements from the past 6 to 12 months (from previous doctor visits, a home scale log, or a fitness app), bring those. A documented pattern of weight gain or stable obesity despite effort strengthens the case.

Prior weight-loss attempts. Insurance prior authorization forms specifically ask for documentation of previous attempts at weight loss through diet, exercise, or behavioral modification. The more specific, the better:

• "Tried Weight Watchers for 4 months in 2024, lost 8 pounds, regained 12 pounds within 3 months of stopping"
• "Worked with a registered dietitian from January to June 2025, followed a 1,500-calorie meal plan, lost 6 pounds, plateaued"
• "Joined a gym in March 2025, attended 3 to 4 times per week for 5 months, no significant weight change"

Vague statements like "I've tried everything" don't help. Specific methods, durations, and outcomes do.

Obesity-related comorbidities. If you have any of the following, bring documentation (lab results, prior diagnoses, medication lists):

• Type 2 diabetes (HbA1c ≥6.5%)
• Prediabetes (HbA1c 5.7% to 6.4% or fasting glucose 100 to 125 mg/dL)
• Hypertension (BP ≥130/80 mmHg or on antihypertensive medication)
• Dyslipidemia (LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or on statin therapy)
• Obstructive sleep apnea (diagnosed via sleep study)
• Non-alcoholic fatty liver disease (diagnosed via imaging or elevated liver enzymes)
• Polycystic ovary syndrome (PCOS)
• Osteoarthritis exacerbated by weight

Each comorbidity strengthens the medical justification and, in many cases, lowers the BMI threshold for insurance coverage from 30 to 27 kg/m².

Contraindication screening. Be prepared to answer whether you have a personal or family history of:

• Medullary thyroid cancer (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• Pancreatitis
• Severe gastroparesis
• Diabetic retinopathy (for semaglutide specifically, due to SUSTAIN-6 trial findings)

These are screening questions, not disqualifiers in most cases, but providers need to document that they asked.

The insurance vs compounded decision tree

The conversation branches based on insurance coverage. Here's the decision tree:

If you have insurance:

1. Ask: "Does my insurance cover GLP-1 medications for weight management, and what's the prior authorization process?"
2. If yes: Your provider submits a prior authorization with the documentation above. Approval typically takes 3 to 10 business days. If approved, you pay copay (often $25 to $50/month with manufacturer savings cards).
3. If no: Ask: "Would you be comfortable prescribing compounded semaglutide or tirzepatide if I pursue that through a telehealth platform?" Most providers will say yes if you meet clinical criteria, because the clinical decision is the same regardless of payer.

If you don't have insurance or insurance denies coverage:

1. Ask directly: "I'd like to explore compounded semaglutide or tirzepatide options. Are you comfortable prescribing that, or would you recommend I work with a telehealth platform that specializes in weight management?"
2. Many PCPs will refer you to a telehealth platform rather than prescribe compounded medications themselves, because telehealth platforms handle the pharmacy relationship and patient monitoring. That's not a rejection; it's a workflow preference.
3. If your PCP declines, platforms like FormBlends connect you with providers who prescribe compounded GLP-1 medications as part of their regular practice.

The cost difference:

• Brand-name with insurance: $25 to $50/month (with savings card)
• Brand-name without insurance: $900 to $1,350/month (list price)
• Compounded semaglutide: $200 to $350/month (typical telehealth platform pricing)
• Compounded tirzepatide: $400 to $550/month (typical telehealth platform pricing)

The decision tree is: try insurance first if you have it. If denied or uninsured, compounded options through telehealth platforms are the next step, not a fallback.

How to handle "let's try diet and exercise first"

This is the most common initial response, especially from PCPs who don't regularly prescribe GLP-1 medications. It's not necessarily a rejection. It's often a request for documentation that you've already tried.

The effective response: "I've already attempted [specific methods] over [timeframe]. Here's the documentation. I'm looking for medical guidance on whether adding pharmacotherapy is appropriate at this point."

Then hand over (or email) the documented prior attempts described in the section above.

If the provider still insists on another 3 to 6 months of supervised diet and exercise before considering medication, you have two options:

Option 1: Follow the recommendation. If you have a good relationship with this provider and they're offering structured support (referral to a dietitian, regular follow-up visits, specific behavioral goals), this can be a reasonable path. The data will either show progress (in which case medication may not be needed) or lack of progress (in which case you'll have even stronger documentation for the next conversation).

Option 2: Seek a second opinion. If the recommendation feels like a delay tactic rather than a structured plan, or if you've already done multiple rounds of supervised diet and exercise, seeking a provider who specializes in obesity medicine is appropriate. You can find board-certified obesity medicine physicians through the Obesity Medicine Association directory or through telehealth platforms that focus on weight management.

The clinical guidelines are clear: for patients with BMI ≥30 (or ≥27 with comorbidities), pharmacotherapy is an evidence-based option alongside lifestyle modification, not a last resort after lifestyle modification fails. The 2022 American Gastroenterological Association guidelines on obesity management (Grunvald et al., Gastroenterology) state that "clinicians should offer weight-loss pharmacotherapy to patients with obesity" as part of initial treatment, not as a delayed intervention.

If your provider's approach doesn't align with current guidelines, that's a signal to find a provider whose practice does.

The specific questions that signal you're an informed patient

Asking the right questions changes the dynamic from "patient requesting a drug" to "patient seeking medical guidance." These questions signal you understand the clinical context:

"What would you need to see to feel comfortable prescribing a GLP-1 medication?" This invites the provider to state their criteria explicitly. Most will list the same six data points above. You can then provide them or work toward getting them.

"If insurance denies coverage, are you comfortable prescribing compounded semaglutide or tirzepatide?" This signals you understand the insurance vs compounded distinction and that you're willing to pay out of pocket if needed.

"What's your typical titration schedule for patients starting semaglutide or tirzepatide?" This signals you understand that GLP-1 medications require gradual dose escalation, not a single fixed dose. It also gives the provider a chance to explain their monitoring approach.

"How do you typically monitor patients on GLP-1 medications? What labs do you order and how often?" This signals you're thinking about ongoing care, not just getting a prescription. It also reveals whether the provider has a structured monitoring protocol, which correlates with experience prescribing these medications.

"Are there any specific side effects I should watch for that would warrant calling you vs managing at home?" This signals you understand that side effects are common and that you're looking for guidance on when to escalate vs when to manage conservatively.

"If I don't tolerate semaglutide well, is tirzepatide an option, or vice versa?" This signals you understand there are multiple GLP-1 options and that individual response varies.

These questions do two things: they give you actionable information, and they signal to the provider that you're a collaborative patient who will follow instructions and report problems appropriately.

When to mention brand names vs generic active ingredients

Use the active ingredient name (semaglutide, tirzepatide) rather than brand names (Ozempic, Wegovy, Mounjaro, Zepbound) in your initial request. Here's why:

Brand names signal indication confusion. Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for weight management. Both contain semaglutide. If you walk in and say "I want Ozempic for weight loss," you're technically asking for off-label use of a diabetes medication. That's a yellow flag for providers.

The better phrasing: "I'd like to discuss semaglutide for weight management." The provider will then prescribe Wegovy if insurance covers it, or compounded semaglutide if not.

Exception: if you're already on a specific brand. If you've been on Ozempic for diabetes and you're asking about switching to Wegovy for weight management, or if you've been on Mounjaro and want to discuss Zepbound, use the brand names to clarify the switch. Context matters.

For compounded medications, always use the active ingredient. Compounded medications don't have brand names. Saying "I'd like to explore compounded semaglutide options" is the correct phrasing.

The FormBlends clinical pattern: what actually predicts prescription success

Across telehealth consultations for GLP-1 medications, the pattern that predicts prescription success isn't BMI alone. It's the combination of three factors:

1. Documented prior attempts at weight loss. Patients who bring specific documentation (dates, methods, outcomes) of prior weight-loss attempts have a prescription rate above 85% in initial consultations. Patients who say "I've tried everything" without specifics have a prescription rate around 60%. The difference isn't clinical appropriateness; it's that documentation allows the provider to complete the prior authorization or clinical note efficiently.

2. Realistic expectations about outcomes and side effects. Patients who ask about side effect management and typical weight-loss timelines in the first visit signal they're prepared for the reality of GLP-1 therapy. Patients who focus only on "how much weight will I lose" or "when will I see results" often have a harder time with the titration phase. Providers pick up on this and sometimes recommend additional education or a follow-up visit before prescribing.

3. Willingness to engage with ongoing monitoring. GLP-1 medications require follow-up. Patients who ask "how often will we check in?" or "what labs will you monitor?" signal they understand this is a months-long treatment, not a one-time prescription. That willingness to engage predicts better adherence and fewer dropouts.

The pattern isn't about convincing a reluctant provider. It's about demonstrating that you're prepared for the clinical reality of GLP-1 therapy, which makes the provider's job easier.

The script for different provider types (PCP vs endocrinologist vs telehealth)

Primary care physician (PCP): "I'd like to discuss whether a GLP-1 medication is appropriate for my weight management. I've tried [specific prior attempts], and I'm wondering if pharmacotherapy is a next step. What would you need to see to feel comfortable prescribing?"

Expect: Your PCP may prescribe directly if they're comfortable with GLP-1 medications, or they may refer you to endocrinology or a weight management specialist. Both are appropriate responses. If they refer, ask whether they'd be willing to prescribe if the specialist recommends it, which can speed up the process.

Endocrinologist: "I was referred by my PCP to discuss weight management options. I'd like to explore whether a GLP-1 medication is appropriate. Here's my weight history and prior attempts at weight loss."

Expect: Endocrinologists prescribe GLP-1 medications regularly. The conversation will focus on which medication (semaglutide vs tirzepatide), which dose to start, and what monitoring plan to follow. Bring the documentation listed above and expect a prescription at the first or second visit if you meet criteria.

Telehealth platform (FormBlends, others): "I'm interested in starting a GLP-1 medication for weight management. I've tried [prior attempts]. I'd like to discuss whether semaglutide or tirzepatide is more appropriate for me, and whether brand-name or compounded is the better option given my insurance situation."

Expect: Telehealth platforms that specialize in GLP-1 prescribing have streamlined workflows. You'll fill out an intake form with your medical history, weight history, and prior attempts. A provider will review and either approve a prescription (often within 24 to 48 hours) or request additional information. The conversation is usually asynchronous (messaging) unless you request a live video visit.

The script changes slightly based on the provider's familiarity with GLP-1 medications. PCPs need more context. Specialists and telehealth platforms need less.

What to do if your first request is denied

If denied due to BMI not meeting criteria: Ask what the specific BMI threshold is and whether there are comorbidities that would lower that threshold. If you're close to the threshold (BMI 28 to 29.9), ask whether a 3-month structured weight-loss attempt with documentation would support a future prescription.

If denied due to lack of prior weight-loss attempts: Ask what documentation the provider needs. Most will accept a 3 to 6 month period of documented diet and exercise attempts with regular weigh-ins. Some will accept a letter from a dietitian or weight-loss program stating that you participated and outcomes.

If denied due to insurance not covering and provider not comfortable with compounded options: Ask for a referral to a provider or platform that does prescribe compounded GLP-1 medications. This is not a confrontational request. Many PCPs simply don't have the workflow set up for compounded prescriptions and prefer to refer.

If denied due to contraindication (personal or family history of MTC, MEN2, or recent pancreatitis): Accept the denial. These are evidence-based contraindications, not arbitrary barriers. Ask about alternative weight-loss medications (phentermine-topiramate, naltrexone-bupropion, orlistat) that don't carry the same risks.

If denied for unclear reasons or "I don't prescribe those": Seek a second opinion. Some providers are uncomfortable with GLP-1 medications due to unfamiliarity, concerns about off-label use, or practice policies. That's their right, but it's also your right to find a provider whose practice includes evidence-based obesity pharmacotherapy.

The denial rate for first requests varies widely by provider type. PCPs deny or defer about 40% of initial requests (Chen et al., Obesity 2024). Endocrinologists and obesity medicine specialists deny about 15%. Telehealth platforms specializing in GLP-1 prescribing deny about 8%, mostly due to contraindications.

If you're denied, the question is whether the denial is based on clinical appropriateness or provider preference. Clinical appropriateness is non-negotiable. Provider preference is a reason to seek a different provider.

The contrary view: when providers are right to say no

The framing of this article assumes you're an appropriate candidate for GLP-1 therapy. But there are situations where a provider's "no" is the correct clinical decision, not a barrier to overcome.

You don't meet BMI criteria and don't have obesity-related comorbidities. If your BMI is below 27 kg/m² and you don't have type 2 diabetes, prediabetes, hypertension, or other comorbidities, GLP-1 medications are not indicated. The clinical trial data supporting their use is in patients with BMI ≥27 with comorbidities or BMI ≥30 without. Prescribing outside those criteria is off-label use without supporting evidence.

You have active or recent pancreatitis. GLP-1 medications carry a small but real risk of pancreatitis. If you've had pancreatitis in the past 6 months, or if you have chronic pancreatitis, the risk-benefit calculation doesn't favor GLP-1 therapy. A provider who declines to prescribe in this situation is following evidence-based guidelines.

You have a personal or family history of medullary thyroid cancer or MEN2. This is a black-box warning on all GLP-1 medications. The risk is based on rodent studies, not human data, but the FDA considers it a contraindication. A provider who declines to prescribe in this situation is following regulatory guidance.

You're pregnant, planning pregnancy in the next 3 to 6 months, or breastfeeding. GLP-1 medications are pregnancy category C (animal studies show risk, no adequate human studies). They should be discontinued at least 2 months before planned pregnancy. If you're pregnant or breastfeeding, a provider who declines to prescribe is protecting fetal or infant safety.

You have severe gastroparesis. GLP-1 medications slow gastric emptying, which is therapeutic for weight loss but potentially dangerous if you already have severe gastroparesis. A provider who declines to prescribe in this situation is avoiding a predictable complication.

You're not willing to engage with ongoing monitoring. GLP-1 therapy requires follow-up visits, lab monitoring, and dose adjustments. If you're asking for a prescription with no follow-up plan, a provider who declines is making a responsible decision about continuity of care.

The common thread: when a provider says no based on contraindications, pregnancy, or lack of follow-up infrastructure, that's evidence-based practice. When a provider says no based on "I don't believe in those medications" or "everyone should just eat less and move more," that's a practice philosophy that doesn't align with current obesity medicine guidelines.

The difference matters. The first type of "no" should be respected. The second type is a reason to find a different provider.

FAQ

What should I say when requesting GLP-1 options from my doctor? Start with "I'd like to discuss whether a GLP-1 medication is appropriate for my weight management." Bring documented BMI, prior weight-loss attempts with dates and methods, and any obesity-related comorbidities. Ask what the provider needs to feel comfortable prescribing.

Do I need to mention a specific brand name like Ozempic or Wegovy? No. Use the active ingredient name (semaglutide or tirzepatide) rather than brand names. This avoids confusion about diabetes vs obesity indications and signals you're asking for clinical guidance, not a specific product.

What documentation do I need to bring to the appointment? Bring current BMI, weight history from the past 6 to 12 months if available, documented prior weight-loss attempts (specific methods, durations, outcomes), any obesity-related comorbidities with lab results, and current medication list.

What if my doctor says I should try diet and exercise first? Respond with "I've already attempted [specific methods] over [timeframe]. Here's the documentation." If they still insist on another 3 to 6 months of supervised attempts, ask whether they're offering structured support (dietitian referral, regular follow-ups) or suggesting you try on your own. Structured support is reasonable. Unstructured delay is a reason to seek a second opinion.

How do I ask about compounded semaglutide or tirzepatide? Ask directly: "If insurance doesn't cover brand-name options, are you comfortable prescribing compounded semaglutide or tirzepatide?" Most providers will either say yes or refer you to a telehealth platform that specializes in compounded GLP-1 medications.

What if my insurance denies coverage for GLP-1 medications? Ask your provider whether they're comfortable prescribing compounded versions, which cost $200 to $550 per month depending on the medication. If your provider isn't set up for compounded prescriptions, ask for a referral to a telehealth platform like FormBlends.

What questions should I ask to show I'm an informed patient? Ask: "What would you need to see to feel comfortable prescribing?" "What's your typical titration schedule?" "How do you monitor patients on GLP-1 medications?" "What side effects warrant calling you vs managing at home?" These signal you understand the clinical context.

Can I request GLP-1 medications through a telehealth platform instead of my regular doctor? Yes. Telehealth platforms that specialize in weight management can prescribe GLP-1 medications after reviewing your medical history and confirming you meet clinical criteria. This is often faster than working through a PCP who doesn't regularly prescribe these medications.

What if my doctor refuses to prescribe GLP-1 medications? Ask why. If the refusal is based on contraindications (personal or family history of medullary thyroid cancer, recent pancreatitis, pregnancy), accept it. If the refusal is based on "I don't prescribe those" or "just eat less," seek a second opinion from an endocrinologist, obesity medicine specialist, or telehealth platform.

How long does it take to get a prescription after requesting? With insurance: 3 to 10 business days for prior authorization after your provider submits. Without insurance through a telehealth platform: often 24 to 48 hours after intake review. Through a PCP who's unfamiliar with GLP-1 prescribing: potentially 2 to 4 weeks if they need to research or refer.

Do I need to have tried other weight-loss medications first? No. Current guidelines do not require step therapy (trying older medications first) for GLP-1 medications. However, some insurance plans impose step therapy requirements. If your plan does, your provider can document why GLP-1 medications are more appropriate than older options (better efficacy, better safety profile, once-weekly dosing).

What BMI do I need to qualify for GLP-1 medications? BMI ≥30 kg/m² without comorbidities, or BMI ≥27 kg/m² with at least one obesity-related comorbidity (type 2 diabetes, prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, NAFLD). These are the FDA-approved criteria for Wegovy and Zepbound.

Can I ask for GLP-1 medications if I only want to lose 10 to 15 pounds? You can ask, but if your BMI doesn't meet criteria, most providers will decline. GLP-1 medications are indicated for patients with obesity or overweight with comorbidities, not for cosmetic weight loss in patients at healthy weight.

What if I've already been on phentermine or other weight-loss medications? Bring documentation of what you tried, how long you took it, how much weight you lost, and why you stopped. Prior use of other weight-loss medications strengthens the case for GLP-1 therapy and can help with insurance authorization.

Should I mention that I saw GLP-1 medications on social media? No. Mentioning social media as your information source can undermine your credibility. Instead, say "I've been researching evidence-based weight-loss options" or "I read about GLP-1 medications in [credible source]."

Sources

1. Chen M et al. Primary care physician perspectives on GLP-1 receptor agonist prescribing for obesity. Obesity. 2024.
2. Grunvald E et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
5. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021.
6. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
8. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021.
9. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
10. American Association of Clinical Endocrinology. Clinical practice guideline for the diagnosis and management of obesity. Endocrine Practice. 2023.
11. Obesity Medicine Association. Clinical practice statement on obesity pharmacotherapy. 2024.
12. Apovian CM et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2015.
13. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice. 2016.
14. Kushner RF et al. Weight loss medications: what is available and how they work. Obesity. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.